Dr. Jeffrey Carson is the Principal Investigator and Study Chair of the MINT trial. He is long time member of the faculty of Rutgers Robert Wood Johnson Medical School and in 2014 he was appointed as one of the two inaugural Provosts of Rutgers Biomedical Health Sciences. He is also the Richard C. Reynolds, M.D. Chair in General Internal Medicine and Distinguished Professor of Medicine. Dr. Carson is an active clinician in outpatient and hospital-based Internal Medicine and on the annual "best" doctor list since 1998. Dr. Carson's expertise in clinical trials has been recognized by his appointment to the Clinical Trials Review Committee at the National Heart, Lung and Blood Institute where he served as Chair during his fifth year. The focus of Dr. Carson's research is determining the risk of anemia and indications for red blood cell blood transfusion. His research has been published in in the New England Journal of Medicine, the Lancet and JAMA. He is author of indications for red blood cell transfusion chapter in UpToDate, published invited review on red cell transfusion in the New England Journal of Medicine, and recently published guidelines for red blood cell transfusion in JAMA. Dr. Carson is principal investigator of the National Heart, Lung and Blood Institutes supported trial called MINT that evaluated red blood cell transfusion thresholds in 3,500 patients with myocardial infarction (MINT Trial; www.minttrial.org). and was published in the New England Journal of Medicine in December 2023.